Literature DB >> 20213807

Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity.

José C Crispín1, Brendan T Keenan, Michele D Finnell, Bonnie L Bermas, Peter Schur, Elena Massarotti, Elizabeth W Karlson, Lisa M Fitzgerald, Sukran Ergin, Vasileios C Kyttaris, George C Tsokos, Karen H Costenbader.   

Abstract

OBJECTIVE: To quantify the expression of CD44 and variant isoforms CD44v3 and CD44v6 on T cells from patients with systemic lupus erythematosus (SLE), and to assess correlations of the level of expression of these molecules with disease manifestations.
METHODS: Information on clinical and demographic characteristics was collected, and blood samples were obtained from 72 patients with SLE and 32 healthy control subjects matched to the patients by sex, race, and age. Expression of CD44 and variants CD44v3 and v6 on T cell subsets was determined by flow cytometry, and Pearson's correlations of their expression levels with clinical variables, SLE Disease Activity Index (SLEDAI) scores, and presence of lupus nephritis were determined. Wilcoxon's rank sum tests and conditional multivariable regression analyses were applied to identify differences in the expression of CD44 between patients with SLE and healthy controls.
RESULTS: Expression of CD44 was higher on CD4+ and CD8+ T cells from SLE patients compared with controls (P <or= 0.03). Expression of CD44v3 and CD44v6 was also higher on total T cells and CD4+ and CD8+ T cells from SLE patients compared with controls (P <or= 0.03). Cell surface levels of CD44v3 on total T cells, CD4+ T cells, and CD8+ T cells as well as cell surface expression of CD44v6 on total T cells and CD4+ T cells were correlated with the SLEDAI score (P < 0.05). The presence of lupus nephritis was associated with the expression of CD44v6 on total T cells, CD4+ T cells, and CD4-CD8- T cells (P < 0.05). Positivity for anti-double-stranded DNA antibodies was associated with the expression levels of CD44v6 on T cells (P < 0.05).
CONCLUSION: These results indicate that expression levels of CD44v3 and CD44v6 on T cells may represent useful biomarkers of SLE activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20213807      PMCID: PMC2879041          DOI: 10.1002/art.27385

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  36 in total

1.  Classification and definition of major flares in SLE clinical trials.

Authors:  M Petri; J Buyon; M Kim
Journal:  Lupus       Date:  1999       Impact factor: 2.911

2.  The CD44 variant isoforms CD44v6 and CD44v7 are expressed by distinct leukocyte subpopulations and exert non-overlapping functional activities.

Authors:  S Seiter; D S Schmidt; M Zöller
Journal:  Int Immunol       Date:  2000-01       Impact factor: 4.823

3.  Constitutive intracellular expression and activation-induced cell surface up-regulation of CD44v3 in human T lymphocytes.

Authors:  C Forster-Horváth; J Bocsi; E Rásó; T I Orbán; E Olah; J Tímár; A Ladányi
Journal:  Eur J Immunol       Date:  2001-02       Impact factor: 5.532

Review 4.  CD44: from adhesion molecules to signalling regulators.

Authors:  Helmut Ponta; Larry Sherman; Peter A Herrlich
Journal:  Nat Rev Mol Cell Biol       Date:  2003-01       Impact factor: 94.444

5.  The CD44v7/8 epitope as a target to restrain proliferation of fibroblast-like synoviocytes in rheumatoid arthritis.

Authors:  A Wibulswas; D Croft; I Bacarese-Hamilton; P McIntyre; E Genot; I M Kramer
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

Review 6.  CD44 cell adhesion molecules.

Authors:  S Goodison; V Urquidi; D Tarin
Journal:  Mol Pathol       Date:  1999-08

7.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.

Authors:  U Günthert; M Hofmann; W Rudy; S Reber; M Zöller; I Haussmann; S Matzku; A Wenzel; H Ponta; P Herrlich
Journal:  Cell       Date:  1991-04-05       Impact factor: 41.582

8.  Influence of epitopes CD44v3 and CD44v6 in the invasive behavior of fibroblast-like synoviocytes derived from rheumatoid arthritic joints.

Authors:  Auragun Wibulswas; Daniel Croft; Andrew A Pitsillides; Ian Bacarese-Hamilton; Peter McIntyre; Elisabeth Genot; Ijsbrand M Kramer
Journal:  Arthritis Rheum       Date:  2002-08

9.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

10.  The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells.

Authors:  I Stamenkovic; A Aruffo; M Amiot; B Seed
Journal:  EMBO J       Date:  1991-02       Impact factor: 11.598

View more
  31 in total

Review 1.  T cells as therapeutic targets in SLE.

Authors:  José C Crispín; Vasileios C Kyttaris; Cox Terhorst; George C Tsokos
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

Review 2.  Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus.

Authors:  Vasileios C Kyttaris; George C Tsokos
Journal:  Curr Opin Rheumatol       Date:  2011-09       Impact factor: 5.006

Review 3.  T cells and IL-17 in lupus nephritis.

Authors:  Tomohiro Koga; Kunihiro Ichinose; George C Tsokos
Journal:  Clin Immunol       Date:  2016-04-21       Impact factor: 3.969

Review 4.  Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective.

Authors:  Vaishali R Moulton; Abel Suarez-Fueyo; Esra Meidan; Hao Li; Masayuki Mizui; George C Tsokos
Journal:  Trends Mol Med       Date:  2017-06-13       Impact factor: 11.951

5.  MIF allele-dependent regulation of the MIF coreceptor CD44 and role in rheumatoid arthritis.

Authors:  Seung-Ah Yoo; Lin Leng; Bum-Joon Kim; Xin Du; Pathricia V Tilstam; Kyung Hee Kim; Jin-Sun Kong; Hyung-Ju Yoon; Aihua Liu; Tian Wang; Yan Song; Maor Sauler; Jurgen Bernhagen; Christopher T Ritchlin; Patty Lee; Chul-Soo Cho; Wan-Uk Kim; Richard Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-21       Impact factor: 11.205

Review 6.  T cells and autoimmune kidney disease.

Authors:  Abel Suárez-Fueyo; Sean J Bradley; David Klatzmann; George C Tsokos
Journal:  Nat Rev Nephrol       Date:  2017-03-13       Impact factor: 28.314

7.  A role for the B-cell CD74/macrophage migration inhibitory factor pathway in the immunomodulation of systemic lupus erythematosus by a therapeutic tolerogenic peptide.

Authors:  Smadar Lapter; Hava Ben-David; Amir Sharabi; Heidy Zinger; Alona Telerman; Maya Gordin; Lin Leng; Richard Bucala; Idit Shachar; Edna Mozes
Journal:  Immunology       Date:  2010-08-25       Impact factor: 7.397

8.  Interleukin-23 deficiency alters thymic selection in lupus-prone mice.

Authors:  H Dai; V C Kyttaris
Journal:  Lupus       Date:  2019-06-05       Impact factor: 2.911

9.  Identification of a systemic lupus erythematosus susceptibility locus at 11p13 between PDHX and CD44 in a multiethnic study.

Authors:  Christopher J Lessard; Indra Adrianto; Jennifer A Kelly; Kenneth M Kaufman; Kiely M Grundahl; Adam Adler; Adrienne H Williams; Caroline J Gallant; Juan-Manuel Anaya; Sang-Cheol Bae; Susan A Boackle; Elizabeth E Brown; Deh-Ming Chang; Lindsey A Criswell; Jeffrey C Edberg; Barry I Freedman; Peter K Gregersen; Gary S Gilkeson; Chaim O Jacob; Judith A James; Diane L Kamen; Robert P Kimberly; Javier Martin; Joan T Merrill; Timothy B Niewold; So-Yeon Park; Michelle A Petri; Bernardo A Pons-Estel; Rosalind Ramsey-Goldman; John D Reveille; Yeong Wook Song; Anne M Stevens; Betty P Tsao; Luis M Vila; Timothy J Vyse; Chack-Yung Yu; Joel M Guthridge; Gail R Bruner; Carl D Langefeld; Courtney Montgomery; John B Harley; R Hal Scofield; Patrick M Gaffney; Kathy L Moser
Journal:  Am J Hum Genet       Date:  2010-12-30       Impact factor: 11.025

Review 10.  Recent insights into the genetic basis of systemic lupus erythematosus.

Authors:  Ornella Josephine Rullo; Betty P Tsao
Journal:  Ann Rheum Dis       Date:  2012-12-19       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.